Monday, December 1, 2008 - 9:27PM EST

Review Articles

31. Benefits of laparoscopic prostate-sparing radical cystectomy.

Author
Rozet F; Harmon J; Arroyo C; Cathelineau X; Barret E; Vallancien G;
Institution
Department of Urology, Institut Montsouris, Universite Rene Descartes, 75674 Paris cedex, France. francois.rozet@imm.fr
Journal
Expert Rev Anticancer Ther. 2006 Jan;6(1):21-6.
Abstract URL
Click here to view abstract

32. Does prolonging the time to bladder cancer surgery affect long-term cancer control: a systematic review of the literature.

Author
Fradet Y; Aprikian A; Dranitsaris G; Siemens R; Tsihlias J; Fleshner N;
Institution
Laval University, CHUQ - Hotel-Dieu de Quebec City, Quebec, Canada.
Journal
Can J Urol. 2006 Jun;13 Suppl 3:37-47.
Abstract URL
Click here to view abstract

33. Nonplatinum therapy in advanced bladder cancer.

Author
Srinivas S; Colocci N;
Institution
Stanford University, 875 Blake Wilbur Drive, Stanford, CA 94305, USA. sandysri@stanford.edu
Journal
Expert Rev Anticancer Ther. 2006 Jun;6(6):887-94.
Abstract URL
Click here to view abstract

34. Systemic chemotherapy options for metastatic bladder cancer.

Author
Siefker-Radtke A;
Institution
Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, 1155 Herman Pressler, Unit 1374, Houston, TX 77030-3721, USA. asiefker@mdanderson.org
Journal
Expert Rev Anticancer Ther. 2006 Jun;6(6):877-85.
Abstract URL
Click here to view abstract

35. Radiotherapy for bladder cancer.

Author
Milosevic M; Gospodarowicz M; Zietman A; Abbas F; Haustermans K; Moonen L; Rodel C; Schoenberg M; Shipley W;
Institution
Radiation Medicine Program, Princess Margaret Hospital, and Department of Radiation Oncology, University of Toronto, Toronto, Ontario, Canada. mike.milosevic@rmp.uhn.on.ca
Journal
Urology. 2007 Jan;69(1 Suppl):80-92.
Abstract URL
Click here to view abstract

36. Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer.

Author
Sternberg CN; Donat SM; Bellmunt J; Millikan RE; Stadler W; De Mulder P; Sherif A; von der Maase H; Tsukamoto T; Soloway MS;
Institution
Department of Oncology, San Camillo Forlanini Hospital, Rome, Italy. cstern@mclink.it
Journal
Urology. 2007 Jan;69(1 Suppl):62-79.
Abstract URL
Click here to view abstract

37. Urinary diversion.

Author
Hautmann RE; Abol-Enein H; Hafez K; Haro I; Mansson W; Mills RD; Montie JD; Sagalowsky AI; Stein JP; Stenzl A; Studer UE; Volkmer BG;
Institution
Department of Urology, Faculty of Medicine, University of Ulm, Ulm, Germany. richard.hautmann@uniklinik-ulm.de
Journal
Urology. 2007 Jan;69(1 Suppl):17-49.
Abstract URL
Click here to view abstract

38. Systemic chemotherapy for advanced bladder cancer: update and controversies.

Author
Garcia JA; Dreicer R;
Institution
Department of Solid Tumor Oncology, Glickman Urologic Institute, Cleveland Clinic Taussig Cancer Center, Cleveland, OH 44195, USA. garciaj4@ccf.org
Journal
J Clin Oncol. 2006 Dec 10;24(35):5545-51.
Abstract URL
Click here to view abstract

39. Trimodality treatment and selective organ preservation for bladder cancer.

Author
Rodel C; Weiss C; Sauer R;
Institution
Department of Radiation Therapy, University of Erlangen, Erlangen, Germany. claus.roedel@strahlen.med.uni-erlangen.de
Journal
J Clin Oncol. 2006 Dec 10;24(35):5536-44.
Abstract URL
Click here to view abstract

40. Superficial and muscle-invasive bladder cancer: principles of management for outcomes assessments.

Author
Parekh DJ; Bochner BH; Dalbagni G;
Institution
Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.
Journal
J Clin Oncol. 2006 Dec 10;24(35):5519-27.
Abstract URL
Click here to view abstract
Pages: 1 2 3 4 5 6